Spectral Diagnostics announced that data demonstrating the clinical utility of its EAA Endotoxin Activity Assay in combination with Toray Medical’s therapeutic column, Toraymyxin, was presented at the Practical Aspects of Extracorporeal Blood Purification in Intensive Care Medicine.
Dr. Alexander Romaschin, Head of Clinical Biochemistry at St. Michael’s Hospital in Toronto and Associate Professor in the Department of Lab Medicine and Department of Surgery at University of Toronto, presented on the effectiveness of sepsis patient management with the use of the combination of Spectral’s EAA assay, the only FDA cleared diagnostic for the measurement of endotoxin, and the Toraymyxin column, which removes endotoxin from the bloodstream. Dr. Romaschin’s presentation was entitled %26quot;Diagnostic and Prognostic Implications of Endotoxemia based on Measurements Using the Endotoxin Activity Assay%26quot;. In addition, Dr. Hisataka Shoji presented data from the Japanese experience using the EAA/Toraymyxin combination.
"There was great enthusiasm for this approach to managing sepsis patients from this prestigious audience of medical doctors from across Russia," said Rob Verhagen, Vice President, Business Development of Spectral. Spectral recently announced that it has expanded its collaboration agreement with Toray to include Russia.
"Dr. Romaschin’s data reaffirms the clinical utility of EAA in combination with extracorporeal blood purification devices, such as Toraymyxin. This combination is gaining increasing recognition and acceptance globally as an effective way to diagnose, treat and monitor patients with endotoxemia," added Dr. Paul Walker, President and CEO of Spectral.
About Toraymyxin
Toraymyxin, a blood purification device, absorbs the bacterial toxin (endotoxin) that causes sepsis and septic shock using a special fiber. It consists of a plastic cylindrical container filled with a special fiber composite immobilized with the antibiotic polymyxin B, which has high affinity for endotoxin. In 1993, Toray received approval for manufacturing and marketing of the product from the "Health and Welfare Ministry of Japan," and Toray Medical has been marketing it since 1994.
Dr. Alexander Romaschin, Head of Clinical Biochemistry at St. Michael’s Hospital in Toronto and Associate Professor in the Department of Lab Medicine and Department of Surgery at University of Toronto, presented on the effectiveness of sepsis patient management with the use of the combination of Spectral’s EAA assay, the only FDA cleared diagnostic for the measurement of endotoxin, and the Toraymyxin column, which removes endotoxin from the bloodstream. Dr. Romaschin’s presentation was entitled %26quot;Diagnostic and Prognostic Implications of Endotoxemia based on Measurements Using the Endotoxin Activity Assay%26quot;. In addition, Dr. Hisataka Shoji presented data from the Japanese experience using the EAA/Toraymyxin combination.
"There was great enthusiasm for this approach to managing sepsis patients from this prestigious audience of medical doctors from across Russia," said Rob Verhagen, Vice President, Business Development of Spectral. Spectral recently announced that it has expanded its collaboration agreement with Toray to include Russia.
"Dr. Romaschin’s data reaffirms the clinical utility of EAA in combination with extracorporeal blood purification devices, such as Toraymyxin. This combination is gaining increasing recognition and acceptance globally as an effective way to diagnose, treat and monitor patients with endotoxemia," added Dr. Paul Walker, President and CEO of Spectral.
About Toraymyxin
Toraymyxin, a blood purification device, absorbs the bacterial toxin (endotoxin) that causes sepsis and septic shock using a special fiber. It consists of a plastic cylindrical container filled with a special fiber composite immobilized with the antibiotic polymyxin B, which has high affinity for endotoxin. In 1993, Toray received approval for manufacturing and marketing of the product from the "Health and Welfare Ministry of Japan," and Toray Medical has been marketing it since 1994.
No comments:
Post a Comment